2016
DOI: 10.1016/j.cep.2016.03.015
|View full text |Cite
|
Sign up to set email alerts
|

Preparation of amorphous drug nanoparticles by high-gravity reactive precipitation technique

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
13
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 19 publications
(13 citation statements)
references
References 36 publications
0
13
0
Order By: Relevance
“…In our present study, free icaritin precipitated when an alkaline solution of icaritin was added dropwise to an acidic solution during vigorous stirring ( Figure 2 a). This process of acid–base precipitation is a type of reactive precipitation [ 9 ]. Therefore, our RPT is suitable for icaritin.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…In our present study, free icaritin precipitated when an alkaline solution of icaritin was added dropwise to an acidic solution during vigorous stirring ( Figure 2 a). This process of acid–base precipitation is a type of reactive precipitation [ 9 ]. Therefore, our RPT is suitable for icaritin.…”
Section: Resultsmentioning
confidence: 99%
“…Based on the results of the above experiments, we conclude that our RPT is the alternative method for preparing AINs. In this process, a high degree of supersaturation was generated immediately due to the decreased solubility of icaritin by acid–base neutralization reactions, which results in a fast nucleation rate and ultrafine particles coated with polymers [ 9 ]. Moreover, toxic organic solvents were avoided in the preparation.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…As the time was short for allowing particle growth, only smaller particles were formed. 23 But when the dropping speed was .4 mL/min, the change in the MPS was not obvious; therefore, the optimum dropping speed was selected as 4 mL/min.…”
Section: Dropping Speedmentioning
confidence: 99%
“…The very low aqueous solubility of CEF contributes to its low a from the gastrointestinal tract [13] and makes it difficult the deve formulations. Several efforts have been performed to overcome this im including preparation of CEF amorphous nanoparticles [14,15] different coformers [16], as well as the use of solid dispersions with d carriers [17][18][19] or of cyclodextrins, alone or in combination with other Moreover, the impact of the above manipulations on the drug bioavailability is often unknown, and these extemporaneous formulations can have limited and unknown physical, chemical and microbiological stability, leading to enhanced risks of medication errors, and the appearance of adverse reactions [4][5][6][7].…”
Section: Introductionmentioning
confidence: 99%